微信在线咨询
| 产品编号 | 产品名称 | 产品包装 | 产品价格 |
| SM8044-10mM | 鞣花酸(98%, HPLC) | 10mM×0.2ml | 80.00元 |
| SM8044-25mg | 鞣花酸(98%, HPLC) | 25mg | 180.00元 |
| SM8044-100mg | 鞣花酸(98%, HPLC) | 100mg | 612.00元 |
| 中文名 | 鞣花酸 |
| 英文名 | Ellagic acid |
| 中文别名 | - |
| 英文别名 | Benzoaric acid; Elagostasine; Lagistase |
| 来源 | 石榴Punica granatum L.；盐肤木Rhus chinensis Mill. |
| 化合物类型 | 酚类(Phenols) |
| 化学式 | C14H6O8 |
| 分子量 | 302.19 |
| CAS号 | 476-66-4 |
| 纯度 | 98%, HPLC |
| 溶剂/溶解度 |
DMSO: 3.33 mg/ml (11.02 mM) Ethanol: < 1 mg/ml (insoluble) Water: < 0.1 mg/ml (insoluble) |
| 溶液配制 | 5mg加入1.65ml DMSO，或者每3.02mg加入1ml DMSO，配制成10mM溶液。 |
| 产品描述 | Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive CK2 inhibitor, with an IC50 of 40 nM and a Ki of 20 nM. | ||||
| 信号通路 | - | ||||
| 靶点 | CK2 | LYN | PKA | SYK | GSK3 |
| IC50 | 40 nM | 2.9 μM | 3.5 μM | 4.3 μM | 7.5 μM |
| 体外研究 | Ellagic acid is a potent CK2 inhibitor, with an IC50 of 40 nM and a Ki of 20 nM. Ellagic acid also blocks other kinases such as LYN, PKA, SYK, GSK3, FGR and CK1, with IC50s of 2.9, 3.5, 4.3, 7.5, 9.4 and 13.0 μM, respectively, and shows no obvious effects on DYRK1a, CSK, NPM-ALK, RET and FLT3 (IC50s > 40 μM). Ellagic acid (5-100 μM) shows inhibitory activities against Karpas299, SUDHL1, SR786, and FE-PD cell lines. Ellagic acid (10 μM) exhibits cytotoxic effects on MCF-7 cells after treatment of radiation. Ellagic acid (10 μM) in combination with Irradiation (IR) significantly abridges the capacity of MCF-7 cells to form colonies equated with individual treatments. Ellagic acid with IR also induces cell apoptosis, and facilitates the upregulation of pro-apopttotic Bax and downregulation of Bcl-2 in MCF-7 cells. | ||||
| 体内研究 | Ellagic acid (EA; 10 mg/kg/day; p.o., 14 days) strongly decreases MDA brain content by 17%, and reduces the levels of brain TNF-α by 42% in rats. Ellagic acid markedly increases the reduced brain contents of 5-HT (39%), dopamine (DA, 71%), and norepinephrine (NE, 77%). Ellagic acid (10 mg/kg, p.o., 14 days) causes decreased histopathological changes induced by Doxorubicin in rats. | ||||
| 临床实验 | NCT04011618: Metabolic Syndrome, Phase 2. | ||||
1.Cozza G, et al. J Med Chem. 2006,49(8):2363-6.
2.Rizk HA, et al. J Biochem Mol Toxicol. 2017 Dec;31(12).
3.Ahire V, et al. Nutr Cancer. 2017,69(6):904-910.
包装清单：| 产品编号 | 产品名称 | 包装 |
| SM8044-10mM | 鞣花酸(98%, HPLC) | 10mM×0.2ml |
| SM8044-25mg | 鞣花酸(98%, HPLC) | 25mg |
| SM8044-100mg | 鞣花酸(98%, HPLC) | 100mg |
| － | 说明书 | 1份 |
-20℃保存，至少一年有效。固体粉末4℃保存，至少一个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
注意事项：本产品可能对人体有一定的毒害作用，请注意适当防护，以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。
微信在线咨询
